Dendritic Cell Based Therapy of Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00197925|
Recruitment Status : Terminated (all patients recruited)
First Posted : September 20, 2005
Last Update Posted : January 3, 2008
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Biological: Onco-peptide loaded autologous dendritic cells||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Vaccination With Autologous Dendritic Cells Pulsed With Onco-Peptides for Treatment of Patients With Metastatic Breast Cancer.A Phase I/II Study|
|Study Start Date :||September 2004|
- Primary aim of the study is to evaluate tolerability and safety of the treatment.
- Secondary aims: evaluation of treatment induced immune response and clinical response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00197925
|Department of Oncology|
|Herlev, Denmark, 2970|
|Principal Investigator:||Inge Marie Svane, MD, PHD||Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark|